metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
ovarian cancer (OC) ovarian cancer (OC)
versus Standard of Care (SoC)
	rucaparib
	ARIEL4, 2022 The Lancet Oncology NCT02855944	RCT	ovarian cancer (OC)	oral rucaparib (600 mg twice daily)	chemotherapy (administered per institutional guidelines)	patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation who had received two or more previous chemotherapy regimens who had received two or more previous chemotherapy regimens	-/-	NA	safety concern	safety concern with 31 % increase in deaths (OS) (not statistically significant) suggested 33 % decrease in progression or deaths (PFS)
	ARIEL3, 2017 Lancet 2017; 390:1949-1961 NCT01968213	RCT	ovarian cancer (OC)			after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma	375 / 189	NA	suggested	suggested 64 % decrease in PFS (extension)
metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)
versus rucaparib
	rucaparib
	ATHENA-COMBO (GOG-3020/ENGOT-ov45), 2021 Int J Gynecol Cancer 2021 Sep 30;ijgc-2021-002933. NCT03522246	RCT	metastatic/advanced OC (mOC) - maintenance (M)	combination of rucaparib (Rubraca®) andnivolumab as maintenance treatment	rucaparib alone	women with newly diagnosed ovarian cancer who responded to their first-line chemotherapy.	-/-	NA	no results	no results from press release May 31 2024 : The primary endpoint of investigator-assessed progression-free survival (PFS) comparing the combination of rucaparib and nivolumab with rucaparib monotherapy was not met in the intent-to-treat (ITT) population